Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion

Neurol Neuroimmunol Neuroinflamm. 2020 Apr 2;7(3):e711. doi: 10.1212/NXI.0000000000000711. Print 2020 May.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alemtuzumab / adverse effects*
  • Anemia, Hemolytic, Autoimmune / blood
  • Anemia, Hemolytic, Autoimmune / chemically induced*
  • Aquaporin 1 / immunology*
  • Autoantibodies / blood
  • Humans
  • Immunologic Factors / adverse effects*
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / drug therapy*
  • Myelitis, Transverse / blood
  • Myelitis, Transverse / drug therapy*
  • Recurrence

Substances

  • AQP1 protein, human
  • Autoantibodies
  • Immunologic Factors
  • Aquaporin 1
  • Alemtuzumab